Coronary Artery Disease Clinical Trial
— FRACTUREOfficial title:
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | March 20, 2026 |
Est. primary completion date | April 20, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Subject is =18 years of age; - Subjects with native coronary artery disease (including stable or unstable angina and silent ischemia) suitable for Percutaneous Coronary Intervention (PCI); - For patients with unstable ischemic heart disease, a local site-based biomarker (preferably troponin or hs-troponin) must be less than or equal to the upper limit of lab normal (ULN) within 12 hours prior to the study procedure; - For patients with stable ischemic heart disease, CK-MB will be drawn at the time of the study procedure from the side port of the sheath; results need not be analyzed prior to enrollment, but must be less than or equal to the upper limit of lab normal (ULN); - Single de novo target lesion stenosis of protected LMCA, or LAD, RCA, or LCX (or of their branches) with: - Stenosis of =70% and <l00%; or - Stenosis =50% and <70% (visually assessed) with evidence of ischemia via positive stress test, or fractional flow reserve value =0.80, or iFR <0.90, or IVUS or OCT minimum lumen area =4.0 mm2; - Evidence of calcification at the target lesion site by - angiography, with fluoroscopic radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, or - Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), with presence of =270 degrees of calcium on at least 1 cross section; - Ability to pass a 0.014" guidewire across the lesion. Key Exclusion Criteria: - Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index procedure; - New York Heart Association (NYHA) class III or IV heart failure at time of index procedure; - Prospective need for hemodynamic support, i.e., IABP or Impella; - Chronic kidney disease with serum creatinine >2.5 mg/dL, eGFR <30 mL/min/1.73m2, or on chronic dialysis; - Unprotected left main diameter stenosis >50%; - Target vessel is excessively tortuous defined as the presence of two or more bends >90º or three or more bends >75º; - Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an unprotected left main lesion; - Chronic Total Occlusion; - Target lesion is located in a native vessel that can only be reached by going through a saphenous vein or arterial bypass graft; |
Country | Name | City | State |
---|---|---|---|
Netherlands | Erasmus Medical Center | Rotterdam | |
United Kingdom | Royal Free Hospital | London | |
United Kingdom | St George's University of London | London | |
United Kingdom | St. Thomas' Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Bolt Medical |
Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Safety Endpoint | Freedom from major adverse cardiac events (MACE) within 30 days following the index procedure. | Within 30 days following procedure | |
Primary | Primary Effectiveness Endpoint | Procedural success defined as successful stent delivery with a final residual stenosis <50% (assessed by angiographic core laboratory) and freedom from in-hospital MACE. | Immediately after the intervention/procedure/surgery | |
Secondary | Device success | The ability to deliver the Bolt IVL catheter across the target lesion, and delivery of lithotripsy without serious angiographic complications immediately after IVL. | Immediately after the intervention/procedure/surgery | |
Secondary | Angiographic success (at <50%) | Stent delivery with <50% final residual stenosis and without serious angiographic complications. | Immediately after the intervention/procedure/surgery | |
Secondary | Procedural success | Stent delivery with a final residual stenosis =30% and without in-hospital MACE. | Immediately after the intervention/procedure/surgery | |
Secondary | Angiographic success (at =30%) | Stent delivery with =30% final residual stenosis and without serious angiographic complications. | Immediately after the intervention/procedure/surgery | |
Secondary | Serious angiographic complications | Severe dissection (Type D to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow. | Immediately after the intervention/procedure/surgery | |
Secondary | MACE | MACE within 6, 12, and 24 months. | within 6, 12, and 24 months. | |
Secondary | Target lesion failure (TLF) | Cardiac death, target vessel myocardial infarction (TV-MI) (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods at 30 days, 6 months, 12 months, and 24 months. | 30 days, 6 months, 12 months, and 24 months | |
Secondary | All deaths, cardiac deaths, MIs, TV-MIs, procedural and nonprocedural MIs, ID-TVRs, ID-TLRs, non-ID-TLRs, non-ID-TVRs, all revascularizations (ID and non-ID), and stent thrombosis | All deaths, cardiac deaths, MIs, TV-MIs, procedural and nonprocedural MIs, ID-TVRs, ID-TLRs, non-ID-TLRs, non-ID-TVRs, all revascularizations (ID and non-ID), and stent thrombosis (Academic Research Consortium (ARC) definite, probable, definite or probable). | Periprocedure, within 30 days, 6 months, 12 months, and 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |